High Dose IV Iron Plus ESA in Chemotherapy-induced Anemia
Status:
Recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
This study is a multicenter, prospective, randomized phase 3 clinical study comparing the
efficacy and safety of the combination treatment of ESA and high-dose IV iron (darbepoietin
alfa + ferric derisomaltose/iron isomaltoside) with ESA monotherapy (darbepoietin alfa alone)
in CIA patients with functional iron deficiency.